This trial is active, not recruiting.

Condition human volunteers
Treatment phenazopyridine hcl
Sponsor Universal Enterprises
Start date August 2008
End date November 2008
Trial size 24 participants
Trial identifier NCT00743977, URG/STEROP/001


The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic product.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification bio-equivalence study
Intervention model crossover assignment
Masking single blind (subject)
Primary purpose basic science
(Active Comparator)
phenazopyridine hcl Pyridium
100mg tablet in fasting state
phenazopyridine hcl Pyridium
100mg tablet in fasting state

Primary Outcomes

The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine
time frame: regular intervals after drug dosing

Eligibility Criteria

Male or female participants from 18 years up to 55 years old.

Inclusion Criteria: - Healthy subjects aged 18 to 55 (Male & Female) - Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests - Informed consent signed by the subject - The subject is co-operative and available for the entire study - Not pregnant or nursing - Normal renal and hepatic function Exclusion Criteria: - Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation - Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma - Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg) - Evidence of chronic or acute infectious diseases; - History or evidence of malignant tumors; - Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl) - Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl) - Planned vaccination during the time course of the study - Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation - Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing - Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription) - Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study - Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day) - Drug addiction - Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week - Subjects who are known or suspected - not to comply with the study directives - not to be reliable or trustworthy - not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed. - to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.

Additional Information

Official title 2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers
Principal investigator Waqar H. Kazmi, M.D, M.S.
Trial information was received from ClinicalTrials.gov and was last updated in August 2008.
Information provided to ClinicalTrials.gov by Universal Enterprises.